Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
3
Neutral
7
Bullish
4
Bearish
3
Neutral
7
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Discovery themes featuring this stock
Krishna Institute of Medical Sciences Limited operates an integrated multi‑specialty hospital network delivering tertiary and quaternary care across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala, focusing on complex specialities such as cardiac sciences, organ transplantation, neurosciences and oncology under the KIMS Hospitals brand.
Q3 FY26 marked a record consolidated quarter with total revenue crossing INR 1,003 crore, driven by higher ARPOB and new hospital contributions, but profitability compressed: EBITDA margin fell to 20.4% and PAT declined materially year‑on‑year due to start‑up losses, higher finance cost and depreciation from recent expansions.
KIMS has been pursuing rapid network growth, commissioning seven hospitals in 2025 and disclosing an overall bed capacity target north of 9,100 beds; management expects most current expansion capex to be complete with FY27 capex of about INR 500–600 crore and subsequent moderation in incremental debt.
Clinical and technology differentiation is evident with multi‑robotic platforms, Tulsa‑Pro and MRgFUS installations and a dominant transplant program; coupled with doctor equity partnerships and O&M models, KIMS Hospitals is leveraging both advanced technology and human capital to bulk up referral volumes and premium case mix.
Healthcare Services
Hospital
30,613 Cr
Low Risk
126.8
58.7
2.2
13.6
810.20
575.55
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockKrishna Institute of Medical Sciences Ltd (KIMS) is currently trading at 787.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Krishna Institute of Medical Sciences Limited operates an integrated multi‑specialty hospital network delivering tertiary and quaternary care across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala, focusing on complex specialities such as cardiac sciences, organ transplantation, neurosciences and oncology under the KIMS Hospitals brand. Q3 FY26 marked a record consolidated quarter with total revenue crossing INR 1,003 crore, driven by higher ARPOB and new hospital contributions, but profitability compressed: EBITDA margin fell to 20.4% and PAT declined materially year‑on‑year due to start‑up losses, higher finance cost and depreciation from recent expansions. KIMS has been pursuing rapid network growth, commissioning seven hospitals in 2025 and disclosing an overall bed capacity target north of 9,100 beds; management expects most current expansion capex to be complete with FY27 capex of about INR 500–600 crore and subsequent moderation in incremental debt. Clinical and technology differentiation is evident with multi‑robotic platforms, Tulsa‑Pro and MRgFUS installations and a dominant transplant program; coupled with doctor equity partnerships and O&M models, KIMS Hospitals is leveraging both advanced technology and human capital to bulk up referral volumes and premium case mix.
Over the past 52 weeks, Krishna Institute of Medical Sciences Ltd has traded between a low of ₹575.55 and a high of ₹810.20. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Krishna Institute of Medical Sciences Ltd has a market capitalization of approximately 30,612.63. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Krishna Institute of Medical Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 126.81 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 30,612.63 Cr, Krishna Institute of Medical Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Krishna Institute of Medical Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Krishna Institute of Medical Sciences Ltd is 126.81. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The feed states FY2025-26 revenue of ₹3,067 crore and profit of ₹404 crore.
KIMS plans to use the funds to fuel its growth strategies, which include capacity expansion, acquiring new hospital facilities, upgrading existing infrastructure, and investing in advanced medical technologies.
The budget's focus on infrastructure development in Tier 2 and Tier 3 cities, coupled with initiatives like medical value tourism hubs, directly supports KIMS's expansion strategy into new regions like Thane and Bangalore, improving accessibility and market reach.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
817.00 | 42,185 Cr | 108.69 | 9.98 | 0.37 | 8.48 | 10.10 | 5.27 | ||
1861.80 | 38,048 Cr | 47.23 | 8.39 | 0.24 | 17.76 | 11.42 | 6.46 | ||
1222.05 | 33,033 Cr | 59.36 | 8.34 | 0.00 | 14.05 | 15.26 | 9.38 | ||
765.05 | 30,613 Cr | 126.81 | 13.62 | 0.00 | 10.74 | 7.99 | 3.12 | ||
439.95 | 13,943 Cr | 104.68 | 6.88 | 0.00 | 6.58 | 9.75 | 4.27 | ||
1340.00 | 13,609 Cr | 48.90 | 8.26 | 0.26 | 16.89 | 16.88 | 10.15 | ||
274.75 | 11,841 Cr | 46.69 | 5.89 | 0.00 | 12.77 | 17.33 | 9.55 | ||
| Median: 7 Co. | — | 817.00 | 30,613 Cr | 59.36 | 8.34 | 0.00 | 12.77 | 11.42 | 6.46 |
Fund Raising
Krishna Institute of Medical Sciences (KIMS) informed exchanges its Board will meet on 13 June 2026 to consider raising funds via issuance of equity, fully convertible warrants and/or other securities through permissible modes; trading window closed.
Fund Raising
Board meeting on 13 Jun 2026 to consider raising funds through issuance of equity, fully convertible warrants or other securities (including preferential/private placement), may convene EGM for shareholder approval; trading window closed until 48 hours after outcome.
